INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,090,000 | +105.7% | 1,000,000 | +150.0% | 0.39% | +201.6% |
| Q2 2023 | $25,328,000 | +16.9% | 400,000 | 0.0% | 0.13% | -9.2% |
| Q1 2023 | $21,660,000 | -8.8% | 400,000 | -10.8% | 0.14% | -25.4% |
| Q4 2022 | $23,738,854 | -15.6% | 448,580 | -25.8% | 0.19% | +5.6% |
| Q3 2022 | $28,116,000 | -44.6% | 604,250 | -32.0% | 0.18% | -39.9% |
| Q2 2022 | $50,718,000 | +59.0% | 888,537 | +70.4% | 0.30% | +106.9% |
| Q1 2022 | $31,907,000 | +564.6% | 521,443 | +468.4% | 0.14% | +700.0% |
| Q4 2021 | $4,801,000 | +40.4% | 91,735 | 0.0% | 0.02% | +28.6% |
| Q3 2021 | $3,420,000 | +43.3% | 91,735 | +57.0% | 0.01% | +40.0% |
| Q2 2021 | $2,386,000 | +610.1% | 58,444 | +453.6% | 0.01% | +400.0% |
| Q4 2020 | $336,000 | – | 10,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |